Use of Psychotropic Medication in the General Population of France, Germany, Italy, and the United Kingdom
The DOI matches its Crossref record.
Abstract
BACKGROUND: The use of psychotropic medications and its association with sleep and psychiatric and physical illnesses were studied in the general population. METHOD: A cross-sectional telephone survey was carried out using the Sleep-EVAL knowledge-base system. A representative sample of the noninstitutionalized general populations of France, Germany, Italy, and the United Kingdom, aged 15 years or over, was interviewed (N = 18,679; participation rate: 78.8%; target population: 204,605,391 inhabitants). Questions were asked about psychotropic medication intake (name of medication, indication, dosage, duration of intake, prescriber), sociodemographics, physical illnesses, and DSM-IV mental disorders. RESULTS: At the time of the interview, 6.4% of the subjects took a psychotropic medication. Anxiolytics were reported by 4.3% of the sample, hypnotics by 1.5%, antidepressants by 1.0%, and neuroleptics and other psychotropics by less than 1.0%. Hypnotics and anxiolytics were mostly used as a sleep disorder treatment. Antidepressants were taken appropriately for a depressive illness in only 44.1% of cases. Low doses of hypnotics and anxiolytics were found in about 10% of cases and low doses of antidepressants in 31.7% of cases. Subjects with a psychiatric disorder received a psychotropic treatment only infrequently (between 10% to 40.4%, depending on the disorder). All psychiatric disorders, including mood disorders, were treated mainly with an anxiolytic. A concomitant physical illness increased the likelihood of using a psychotropic treatment and was a strong predictor of adequate psychotropic dosage. CONCLUSION: Psychiatric pathology and sleep disorders remained mostly untreated or inadequately managed in the general population. Depression is underdiagnosed by the physicians and is treated with antidepressant in only 7% of cases. By contrast, anxiolytics are extensively prescribed, especially in France and Italy. The co-occurrence of organic and psychiatry disorders increases the frequency of medical consultations and the likelihood of being given a prescription for the mental disorder.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“adding CBT was of limited value in one trial, 22 but facilitated discontinuation in other trials. 23,24”
From Comparative efficacy of two interventions to discontinue long-term benzodiazepine use: cluster randomised controlled trial in primary care (2014) · cites this paper as [22]
In the citing paper
“a brief GP intervention based on gradual dose reduction, resulting in 3-12 months discontinuation rates of 51% and 45% respectively. 14,22”
From Comparative efficacy of two interventions to discontinue long-term benzodiazepine use: cluster randomised controlled trial in primary care (2014) · cites this paper as [22]
In the citing paper
“The results of studies on such strategies have been inconsistent.”
From Comparative efficacy of two interventions to discontinue long-term benzodiazepine use: cluster randomised controlled trial in primary care (2014) · cites this paper as [22]
Citations
Cites
Still being checked.
Cited by
Items 101–200 of 271
Liu, X., Ye, W., Watson, P., & Tepper, P. G. (2010) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0b013e3181e9daf7 · Cited by 26
Exploring the dark side of the moon: the treatment of benzodiazepine tolerance
Lugoboni, F., & Quaglio, G. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12148 · Cited by 21
Benson, T., O’Neill, S. M., Murphy, S. M., Ferry, F. R., & Bunting, B. P. (2014) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796014000547 · Cited by 21
Silva, M. A. D., Dugravot, A., Balkau, B., Roussel, R., Fumeron, F., Elbaz, A., Canonico, M., Singh‐Manoux, A., Nabi, H., & the D.E.S.I.R. Study Group (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv153 · Cited by 22
Alosaimi, F. D., Alruwais, F. S., Alanazi, F. A., Alabidi, G. A., Aljomah, N., & Al-Salameh, N. S. (2016) · Neurosciences · doi:10.17712/nsj.2016.4.20160245 · Cited by 22
Use of addictive anxiolytics and hypnotics in a national cohort of incident users in Norway
Kjosavik, S. R., Ruths, S., & Hunskaar, S. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1124-2 · Cited by 21
Psychotropic Drug Use in Israel
Grinshpoon, A., Marom, E., Weizman, A., & Ponizovsky, A. M. (2007) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v09n0504 · Cited by 21
Wainstein, L., Victorri‐Vigneau, C., Sebille, V., Hardouin, J.-B., Feuillet, F., Pivette, J., Chaslerie, A., & Jolliet, P. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283400cb2 · Cited by 22
Menear, M., Doré, I., Cloutier, A., Perrier, L., Roberge, P., Duhoux, A., Houle, J., & Fournier, L. (2015) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2015.01.001 · Cited by 23
Hausken, A. M., Skurtveit, S. O., Rosvold, E. O., Bramness, J. G., & Furu, K. (2007) · Scandinavian Journal of Public Health · doi:10.1080/14034940601159161 · Cited by 20
Micallef, J., & Lapeyre‐Mestre, M. (2009) · Therapies · doi:10.2515/therapie/2009054 · Cited by 19
Hove, O., Biringer, E., Havik, O. E., Aßmus, J., Braatveit, K. J., Holm, S. E. H., & Hermann, M. (2019) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4741 · Cited by 19
Anxiolytic and hypnotic drug misuse in Thailand: Findings from a national household survey
Assanangkornchai, S., Sam‐angsri, N., RERNGPONGPAN, S., & EDWARDS, J. G. (2010) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2009.00092.x · Cited by 22
Subramaniam, M., He, V. Y., Vaingankar, J. A., Abdin, E., & Chong, S. A. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-231 · Cited by 20
Incidence and Characteristics of Benzodiazepine Use in an Elderly Cohort: The EVA Study
Lechevallier‐Michel, N., Berr, C., & Fourrier‐Réglat, A. (2005) · Therapies · doi:10.2515/therapie:2005078 · Cited by 18
Rubio, G., Bobes, J., Cervera, G., Terán, A., Pérez, M., López-Gómez, V., & Rejas, J. (2011) · European Addiction Research · doi:10.1159/000324850 · Cited by 21
Acquaviva, É., Peyre, H., & Falissard, B. (2011) · Neuropsychiatrie de l Enfance et de l Adolescence · doi:10.1016/j.neurenf.2011.10.009 · Cited by 20
Burnout, Depression und Substanzgebrauch bei deutschen Psychiatern und Nervenärzten
Schönfeldt‐Lecuona, C., Kessler, H., Beck, J., Beschoner, P., Freudenmann, R. W., & Braun, M. (2008) · Nervenheilkunde · doi:10.1055/s-0038-1627220 · Cited by 18
Antidepressants and AgePreprint
Blanchflower, D. G., & Oswald, A. J. (2011) · SSRN Electronic Journal · doi:10.2139/ssrn.1872733 · Cited by 24
HRB National psychological wellbeing and distress survey: baseline results
Doherty, D. T., Moran, R., Kartalova‐O’Doherty, Y., & Walsh, D. (2007) · Lenus, The Irish Health Repository (Dr Steevens Hospital Library) · Cited by 18
Mercier, A., Bénichou, J., Aubin-Auger, I., Lebeau, J., Houivet, E., Royen, P. V., & Peremans, L. (2015) · Annals of General Psychiatry · doi:10.1186/s12991-015-0041-7 · Cited by 17
Continuous Infusion of Flumazenil in the Management of Benzodiazepines Detoxification
Benini, A., Gottardo, R., Chiamulera, C., Bertoldi, A., Zamboni, L., & Lugoboni, F. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.646038 · Cited by 19
Addressing the Issue of Chronic, Inappropriate Benzodiazepine Use: How Can Pharmacists Play a Role?
Gallagher, H. C. (2013) · Pharmacy · doi:10.3390/pharmacy1020065 · Cited by 21
Vicens, C., Leiva, A., Bejarano‐Romero, F., Sempere, E., Rodríguez-Rincón, R. M., Fiol, F., Mengual, M., Ajenjo-Navarro, A., do Pazo-Oubiña, F., Mateu, C., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-022046 · Cited by 22
Sleep medication and melatonin use among Norwegian nurses – A cross‐sectional study
Forthun, I., Waage, S., Pallesen, S., Moen, B. E., & Bjorvatn, B. (2021) · Nursing Open · doi:10.1002/nop2.1057 · Cited by 18
Systemic model of chronic benzodiazepine use among mature adults
Pérodeau, G., Grenon, É., Grenier, S., & O’Connor, K. P. (2015) · Aging & Mental Health · doi:10.1080/13607863.2015.1015961 · Cited by 17
Sleep problems in depression: how do they impact treatment and recovery?
Wade, A. G. (2006) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500600552594 · Cited by 20
Variability in market uptake of psychotropic medications in Europe reflects cultural diversity
Hoebert, J. M., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & van Dijk, L. (2017) · BMC Health Services Research · doi:10.1186/s12913-017-2649-6 · Cited by 17
Determinants of Coprescription of Anxiolytics with Antidepressants in General Practice
Verger, P., Saliba‐Serre, B., Rouillon, F., Kovess–Masféty, V., Villani, P., Bouvenot, G., & Lovell, A. M. (2008) · The Canadian Journal of Psychiatry · doi:10.1177/070674370805300204 · Cited by 17
Santos-Pérez, M. I., Fierro, I., Salgueiro, E., Sáinz-Gil, M., & Arias, L. H. M. (2019) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2019-001927 · Cited by 15
Crude and Adjusted Prevalence of Sleep Complaints in Mexico City
Jiménez‐Genchi, A., & Caraveo-Anduaga, J. J. (2017) · Sleep Science · doi:10.1016/j.slsci.2017.02.001 · Cited by 17
Use of psychotropic medication in Santiago, Chile
Rojas, G., Rosemarie Fritsch, M., Gaete, J., González, I. M., & Araya, R. (2005) · Journal of Mental Health · doi:10.1080/09638230500195221 · Cited by 15
Anxiety disorders: Prevalence, comorbidity and outcomes
Ohayon, M. M. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.07.001 · Cited by 16
Self-citationWhy do general practitioners prescribe antidepressants to their patients? A pilot study
Mercier, A., Auger-Aubin, I., Lebeau, J.-P., Schuers, M., Boulet, P., Van Royen, P., & Peremans, L. (2014) · BioPsychoSocial Medicine · doi:10.1186/1751-0759-8-17 · Cited by 14
Natural history in Malan syndrome: survey of 28 adults and literature review
Huynh, T. N., Delagrammatikas, C. G., Chiriatti, L., Panfili, A., Ventarola, K., Menke, L. A., Tartaglia, M., Huisman, S. A., & Priolo, M. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03288-6 · Cited by 14
Ten-year trend in sleeping pills use in Switzerland: the CoLaus study
Abolhassani, N., Haba‐Rubio, J., Heinzer, R. C., Vollenweider, P., & Marques-Vidal, P. M. (2019) · Sleep Medicine · doi:10.1016/j.sleep.2018.06.022 · Cited by 15
Netto, M. U. D. Q., de Freitas, O., & Pereira, L. R. L. (2012) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 14
A Sleep Education and Hypnotics Reduction Program for Hospitalized Patients at a General Hospital
Chung, S., Youn, S., Park, B., Lee, S., & Kim, C. (2018) · Psychiatry Investigation · doi:10.4306/pi.2018.15.1.78 · Cited by 13
Lugoboni, F., Mirijello, A., Morbioli, L., Arzenton, E., Leone, R., Faccini, M., Casari, R., Cosmo, S. D., Gasbarrini, A., & Addolorato, G. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1457646 · Cited by 13
Sleep-medication for symptomatic insomnia in the general population of Japan
Doi, Y., Minowa, M., Uchiyama, M., & Okawa, M. (2005) · Sleep and Biological Rhythms · doi:10.1111/j.1479-8425.2005.00182.x · Cited by 14
Comparison of psychotropic medication use in the Baltic countries
Harro, J., Aadamsoo, K., Rootslane, L., Laius, O., O’Leary, A., Adomaitienė, V., Kupca, B., Lehtmets, A., Navickas, A., Rancāns, E., et al. (2019) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2019.1707283 · Cited by 12
Shift work and use of psychotropic medicine: a follow-up study with register linkage
Albertsen, K., Hannerz, H., Nielsen, M. L., & Garde, A. H. (2019) · Scandinavian Journal of Work Environment & Health · doi:10.5271/sjweh.3872 · Cited by 12
Chen, T., Winkelman, J. W., Mao, W., Tzeng, N., Kuo, T. B. J., Yang, C. C. H., Tsai, H., & Wu, C. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15033 · Cited by 14
High-Dose Benzodiazepine Users' Perceptions and Experiences of Anterograde Amnesia.
Liebrenz, M., Schneider, M., Buadze, A., Gehring, M.-T., Dube, A. R., & Caflisch, C. (2016) · PubMed · doi:10.7892/boris.89433 · Cited by 13
Duncan, P. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781139025515.013 · Cited by 12
Antidepressant Pharmacoepidemiology in a General Population Sample
Patten, S. B., Williams, J. V. A., Wang, J., Adair, C. E., Brant, R., Casebeer, A. L., & Barbui, C. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000162815.07442.5a · Cited by 12
Lévy, L., Martin‐Guehl, C., Lechevallier‐Michel, N., Noïze, P., Moore, N., Latry, P., & Fourrier‐Réglat, A. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1224 · Cited by 12
Correlates and psychiatric disorders associated with psychotropic drug use in Taiwan
Chien, I., Bih, S., Lin, C.-H., Chou, Y., Lee, W.-G., Lee, C., & Chou, P. (2009) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-009-0169-3 · Cited by 11
Raoof, M., Nawaz, H., Nusrat, R., Pabaney, A. H., Randhawa, A. R., Rehman, R., Rizvi, N. B., & Naqvi, H. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001804 · Cited by 11
Lugoboni, F., Bertoldi, A., Casari, R., Mantovani, E., Morbioli, L., & Tamburin, S. (2020) · European Addiction Research · doi:10.1159/000507852 · Cited by 15
Zamboni, L., Portoghese, I., Congiu, A., Zandonai, T., Casari, R., Fusina, F., Bertoldi, A., & Lugoboni, F. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.811130 · Cited by 11
Rebound and withdrawal with benzodiazepine and non-benzodiazepine hypnotic medication
LADER, M. H. (2006) · Birkhäuser-Verlag eBooks · doi:10.1007/3-7643-7440-3_15 · Cited by 10
Self-citationOccupational Injuries and Use of Benzodiazepines: A Systematic Review and Metanalysis
Garbarino, S., Lanteri, P., Bragazzi, N. L., Gualerzi, G., & Riccò, M. (2021) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2021.629719 · Cited by 13
Boeuf-Cazou, O., Niezborala, M., Marquié, J.-C., & Lapeyre‐Mestre, M. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1911 · Cited by 10
Dispensing of psychotropic drugs to adults in community pharmacies in Latvia
Vrublevska, K., Rukmane, J., Burmistrs, R., Sīpols, A. J., & Muceniece, R. (2008) · Pharmacy World & Science · doi:10.1007/s11096-008-9256-x · Cited by 10
Rapid detoxification of benzodiazepine or Z-drugs dependence using acetylcholinesterase inhibitors
Lin, S. (2014) · Medical Hypotheses · doi:10.1016/j.mehy.2014.03.032 · Cited by 10
Medication use in community-dwelling older people: pharmacoepidemiology of psychotropic utilisation
Schäfers, A., Martini, N. D., Moyes, S. A., Hayman, K., Zolezzi, M., McLean, C., & Kerse, N. M. (2014) · Journal of Primary Health Care · doi:10.1071/hc14269 · Cited by 10
Forthun, I., Waage, S., Pallesen, S., Moen, B. E., & Bjorvatn, B. (2022) · Occupational and Environmental Medicine · doi:10.1136/oemed-2022-108251 · Cited by 9
Haaramo, P., Lallukka, T. M., Lahelma, E. T., Hublin, C., & Rahkonen, O. (2014) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-014-0862-8 · Cited by 10
Detoxification Improves Multidomain Cognitive Dysfunction in High-Dose Benzodiazepine Abusers
Federico, A., Lugoboni, F., Mantovani, E., Martini, A., Morbioli, L., Casari, R., Faccini, M., & Tamburin, S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00747 · Cited by 9
Xu, J., & Yanfei, D. (2013) · Journal of Mental Health · doi:10.3109/09638237.2013.819419 · Cited by 11
Engberink, A. O., Carbonnel, F., David, M., Norton, J. L., Bourrel, G., Boulenger, J., & Capdevielle, D. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716639922 · Cited by 9
Federico, A., Mantovani, E., Casari, R., Bertoldi, A., Lugoboni, F., & Tamburin, S. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02285-w · Cited by 9
Substance Use Disorders: A Biopsychosocial Perspective
Duncan, P. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781139025515 · Cited by 11
Évaluation de la prescription d’antipsychotiques en médecine générale : conséquences métaboliques
Gignoux-Froment, F., de Montleau, F., Saravane, D., & Verret, C. (2012) · L Encéphale · doi:10.1016/j.encep.2011.12.006 · Cited by 8
Chronic psychotropic drug use among frail elderly women receiving home care services
Pérodeau, G., Paradis, I., Grenier, S., O'Connor, K., & Grenon, É. (2011) · Journal of Women & Aging · doi:10.1080/08952841.2011.611070 · Cited by 7
“Prescribing psychotropic drugs to reduce symptoms of anxiety and insomnia among the elderly is common practice in many countries (Ohayon & Lader, 2002).”
BackgroundHausken, A. M., Furu, K., Tverdal, A., & Skurtveit, S. O. (2010) · Scandinavian Journal of Public Health · doi:10.1177/1403494810370229 · Cited by 8
Ilomäki, R., Ilomäki, E., Hakko, H. H., & Räsänen, P. K. (2010) · Addictive Behaviors · doi:10.1016/j.addbeh.2010.09.003 · Cited by 7
The Sleeping Pill Prescription Rate for Inpatients at a General Hospital
Youn, S., Hann, C.-W. C., Park, B., Lee, S., Kim, C., Yi, K., & Chung, S. (2016) · Sleep Medicine Research · doi:10.17241/smr.2016.00045 · Cited by 7
Reintroduction of quazepam: an update on comparative hypnotic and adverse effects
Moniri, N. H. (2019) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000277 · Cited by 7
Darmon, D., Laforest, L., Ganse, E. H. V., Petrazzuoli, F., van Weel, C., & Letrilliart, L. (2015) · BMC Family Practice · doi:10.1186/s12875-015-0222-0 · Cited by 7
Pérodeau, G., & Cappeliez, P. (2007) · European Review of Applied Psychology · doi:10.1016/j.erap.2005.01.001 · Cited by 8
Polygenic dissection of treatment-resistant depression with proxy phenotypes in the UK Biobank
Wang, L.-H., Shih, M.-Y., Lin, K., Kuo, P., & Feng, Y. A. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.04.012 · Cited by 7
Mitotic recombination: a genotoxic effect of the antidepressant citalopram in Aspergillus nidulans
Franco, C. C. S., de Castro-Prado, J., ROSADA, L. J., de Sant’Anna, J. R., & de Castro‐Prado, M. A. A. (2010) · Experimental Biology and Medicine · doi:10.1258/ebm.2010.010159 · Cited by 6
Psychotropic Drug Use Among the Elderly: Risk Factors Involved in Long-Term Use
Aubron, V., Camus, V., Bouazzaoui, B., Pélissolo, A., & Michel, G. (2010) · Substance Use & Misuse · doi:10.3109/10826080903550521 · Cited by 6
Tsay, W.-Y., Chen, L., Wu, S., Hsiao, P., Ting, T., Yen, C., Chang, S., Li, C., Yang, H., Yen, C.-F., et al. (2024) · BMC Public Health · doi:10.1186/s12889-024-20778-1 · Cited by 5
Occupation type, family demands and mental health: analysis of linked administrative data
Ferry, F. R., Rosato, M., Curran, E., & Leavey, G. (2023) · Journal of Mental Health · doi:10.1080/09638237.2023.2182416 · Cited by 5
Prevalence and determinants of psychotropic medication use in Poland
Pisarska, A., Stokwiszewski, J., & Moskalewicz, J. (2023) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/159734 · Cited by 5
Authier, N., Boucher, A., LAMAISON, D., Llorca, P., Descotes, J., & Eschalier, A. (2009) · Therapies · doi:10.2515/therapie/2009051 · Cited by 5
Factors associated with common mental disorders and use of psychiatric drugs in cancer outpatients
Shirama, F. H., Silva, T. B., dos Santos, J. C., de Oliveira, P. A., de Oliveira, J. I., Borges, T. L., & Miasso, A. I. (2019) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2019.06.001 · Cited by 7
Psychoactive drugs in the Brazilian public health system: Use profile and associated factors
Siani-Morello, M. R., Pereira, L. B., Ferreira, I. M. D. L., Aliste, M. J., & Pereira, L. R. L. (2022) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902022e19739 · Cited by 8
Gallini, A., Yrondi, A., Cantet, C., Poncet, M., Vellas, B. J., Schmitt, L., & Andrieu, S. (2019) · The journal of nutrition health & aging · doi:10.1007/s12603-019-1252-4 · Cited by 5
Hannerz, H., Albertsen, K., Nielsen, M. L., & Garde, A. H. (2020) · JMIR Research Protocols · doi:10.2196/18236 · Cited by 5
Norton, J. L., David, M., & Boulenger, J. (2007) · The European Journal of Psychiatry · doi:10.4321/s0213-61632007000100008 · Cited by 5
Berthelon, C., de Longcamp, A. L. F., Coquerel, A., & Denise, P. (2007) · European Review of Applied Psychology · doi:10.1016/j.erap.2006.06.001 · Cited by 5
High-dose benzodiazepine use and QTc interval prolongation, a latent class analysis study
Zamboni, L., Portoghese, I., Casari, R., Fusina, F., Santin, L., Lecca, L. I., Campagnari, S., Carli, S., Zandonai, T., & Lugoboni, F. (2024) · Scientific Reports · doi:10.1038/s41598-023-50489-3 · Cited by 4
Antidepressants for Economists and Business-School Researchers: An Introduction and Review
Katolik, A., & Oswald, A. J. (2017) · Die Unternehmung · doi:10.5771/0042-059x-2017-4-448 · Cited by 4
Colman, L., Delaruelle, K., & Bracke, P. (2022) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-022-02283-1 · Cited by 4
Trépel, D., Ali, S., Gilbody, S. M., Leiva, A., McMillan, D., Bejarano‐Romero, F., Sempere, E., & Vicens, C. (2020) · HRB Open Research · doi:10.12688/hrbopenres.13049.1 · Cited by 5
High-dose benzodiazepine dependence among health-care professionals: A neglected phenomenon
Morbioli, L., & Lugoboni, F. (2021) · Medicine Science and the Law · doi:10.1177/0025802420928650 · Cited by 7
Hypnotic consumption in the Portuguese population: data from the National Health Survey 1998–1999
Marques-Vidal, P. M., & Dias, C. M. (2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1133 · Cited by 7
Câmara, H. E. D. S., Rocha, C., & Balteiro, J. (2011) · Revista Portuguesa de Saúde Pública · doi:10.1016/s0870-9025(11)70021-9 · Cited by 4
Lin, C., Chiou, H., Chang, Y., Liu, J., Hung, Y., Chuang, M., & Chien, L. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3963 · Cited by 6
Syed, S. B., Riaz, M. U., Mehnaz, G., Iftikhar, A., Khan, T. M., Zainab, S., Bukhari, S., & Zulfiqar, R. (2024) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.53555/jptcp.v31i3.5191 · Cited by 3
Use of Drugs Subject to Controlled Prescriptions: a Retrospective Analysis
Demircan, D., Gülmez, S. E., Dönertaş, B., Topçu, İ., Yilmaz, H., Berkman, K., & Akıcı, A. (2012) · Balkan Medical Journal · doi:10.5152/balkanmedj.2012.073 · Cited by 3
Efficacy of Disseminating Educational Materials in General Practices
Ulbricht, S., Gross, B., Kunstmann, W., John, U., & Meyer, C. (2014) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/0939-5911.a000298 · Cited by 4
Youn, S., Lee, S., Kim, C., & Chung, S. (2019) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2019.17.4.542 · Cited by 3
Cross-country variation in medicines use; a pharmaceutical system perspective
Hoebert, J. M. (2013) · Utrecht University Repository (Utrecht University) · Cited by 5
Prevalence of benzodiazepines misuse in Ubon Ratchathani province Thailand.
Puangkot, S., Laohasiriwong, W., Saengsuwan, J., & Chiawiriyabunya, I. (2011) · PubMed · Cited by 2
Prescribing Psychotropics: Misuse, Abuse, Dependence, Withdrawal and Addiction
(2021) · Frontiers research topics · doi:10.3389/978-2-88966-940-0 · Cited by 2
Metadata
- Authors
- Ohayon, M. M., & Lader, M. H.
- Affiliations
- Stanford Medicine (US)
- ORCID
- Ohayon, Maurice M.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2002-09-15
- Volume
- 63
- Issue
- 9
- Pages
- 817-825
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2137401427
- Cited by
- 271
- References
- 0
- Citations by year
- 2025: 3 · 2024: 10 · 2023: 5 · 2022: 5 · 2021: 5 · 2020: 33 · 2019: 10 · 2018: 7 · 2017: 10 · 2016: 11 · 2015: 12 · 2014: 11 · 2013: 11 · 2012: 11
- FWCI
- 15.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- psychotropic drug use, anxiolytics, hypnotics, antidepressants, antipsychotic drugs, sleep disorders, underdiagnosis of depression, mental illness, prescribing patterns, general population
- MeSH terms
- Adolescent, Adult, Aged, Antidepressive Agents, Mental Disorders, Cross-Cultural Comparison, Drug Utilization, Expert Systems, Female, France, Germany, United Kingdom, Humans, Hypnotics and Sedatives, Italy, Male, Middle Aged, Practice Patterns, Physicians', Psychotropic Drugs, Sleep Wake Disorders, Anti-Anxiety Agents, Comorbidity, Logistic Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.